SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer.
about
Clinical results of randomized trials and 'real-world' data exploring the impact of Bevacizumab for breast cancer: opportunities for clinical practice and perspectives for research.Neoadjuvant Bevacizumab plus Chemotherapy versus Chemotherapy Alone to Treat Non-Metastatic Breast Cancer: A Meta-Analysis of Randomised Controlled TrialsGermline Genetic Variants in TEK, ANGPT1, ANGPT2, MMP9, FGF2 and VEGFA Are Associated with Pathologic Complete Response to Bevacizumab in Breast Cancer Patients.Nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy of breast cancer: a systematic review and meta-analysis.Neoadjuvant Chemotherapy In Triple-Negative Breast Cancer: A Multicentric Retrospective Observational Study In Real-Life Setting.The use of systemic therapies to prevent progression of inflammatory breast cancer: which targeted therapies to add on cytotoxic combinations?Recent Advances in the Neoadjuvant Treatment of Breast Cancer.Outcomes of patients with inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes: A population-based study from the SEER program.Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance.Nanomedicine applications in the treatment of breast cancer: current state of the art.Bevacizumab significantly increases the risks of hypertension and proteinuria in cancer patients: A systematic review and comprehensive meta-analysis.Similar response profile to neoadjuvant chemotherapy, but different survival, in inflammatory versus locally advanced breast cancers.The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40.Scientific Summary from the Morgan Welch MD Anderson Cancer Center Inflammatory Breast Cancer (IBC) Program 10th Anniversary Conference.Effect of antitumor treatments on triple-negative breast cancer patients: A PRISMA-compliant network meta-analysis of randomized controlled trials.Assessment of early response biomarkers in relation to long-term survival in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: Results from the Phase II PROMIX trial.Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going.Is complete response the answer?The Effect of Perioperative Bevacizumab on Disease-Free and Overall Survival in Locally Advanced HER-2 Negative Breast Cancer: A Meta-Analysismouse study identifies tumour growth kinetics as biomarkers for the outcome of anti-angiogenic treatment
P2860
Q31157714-C3355F40-5161-41CE-AB22-D6A4643E4533Q35881780-DA172083-C4A2-4FAF-B8D2-998FE79AA2BEQ36237852-3EF28BB4-9370-4FD6-95C2-B421B7EED7C3Q37725620-BD189C8F-05C9-43A8-9189-2D78F9625EB6Q38677841-35D4F90C-A8AD-452D-825F-2B8740C4A6F0Q38683638-3F73719E-0C5A-4E12-A922-13EE8D938710Q38687392-80AEDC96-5A79-42AB-9E94-BC72B0CEA233Q38803734-FA1ACA4B-C4AB-4B76-9919-7F1AEC7B44D8Q41291930-EBBB437F-3EB5-43BC-9F5B-A3E28882EA31Q41483629-F7945BEB-149E-4E2A-9B3C-CE1284912E23Q41612851-EAA051C1-B984-4DC2-B736-57FAE0872DE4Q42371602-8A5A435D-C039-4005-A307-6BCCE8B4F17CQ45047438-E75DC63D-2B2C-4E9E-8A98-7C2E887F152BQ45916506-13D3FD28-ED21-47C6-94D9-EA288D3E5186Q47121796-1CA82845-268B-4847-BF83-27EF5F311DA4Q47757066-E2F39DB3-DFB7-4DF4-AD54-F574EEAB3EB9Q49303842-C3A0022D-1192-4F39-B3AE-074DF49A86BBQ54467225-6E3A02A1-BFB9-49E2-B81D-AD4F76DFE844Q57108158-48F63547-50D3-45ED-AA73-0C78B00840C0Q58718463-445B0D01-2229-4FFE-8106-BFE6ADCF25E0
P2860
SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 08 July 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
SWOG S0800 (NCI CDR0000636131) ...... ocally advanced breast cancer.
@en
SWOG S0800
@nl
type
label
SWOG S0800 (NCI CDR0000636131) ...... ocally advanced breast cancer.
@en
SWOG S0800
@nl
prefLabel
SWOG S0800 (NCI CDR0000636131) ...... ocally advanced breast cancer.
@en
SWOG S0800
@nl
P2093
P2860
P1476
SWOG S0800 (NCI CDR0000636131) ...... ocally advanced breast cancer.
@en
P2093
A F Schott
G N Hortobagyi
H R Mirshahidi
J R Gralow
R B Livingston
S Chennuru
P2860
P2888
P304
P356
10.1007/S10549-016-3889-6
P407
P50
P577
2016-07-08T00:00:00Z